What is the role of targeted therapy in relapsed/refractory ALK+ anaplastic large cell lymphoma?  

Would you use ALK inhibitors such as crizotinib based on recent phase II data?

Are there any research efforts to combine ALK inhibitors with current available therapies, such as brentuximab vedotin?

Answer from: at Academic Institution